SEC Filing Summary for Abeona Therapeutics Inc.

This SEC filing details a transaction by Keith A. Goldan, a director at Abeona Therapeutics Inc. On April 1, 2026, Goldan acquired 32,751 shares of Common Stock via a Form 4 filing. The acquisition was marked with transaction code "A" and a price of $0.00 per share, indicating it was likely a grant or award. All acquired shares are subject to vesting on April 1, 2027, as noted in footnote F1. Following this transaction, Goldan directly owns 32,751 shares of the company's stock. The filing was signed by Joseph Vazzano as Attorney-in-Fact on April 7, 2026.